The launch of the first GLP-1 pill for obesity in the United States by Novo Nordisk marks a significant milestone in the treatment of weight management. On Monday, the company officially announced this development, presenting new options for the millions grappling with obesity in the U.S.
The Wegovy pill, which represents a groundbreaking advancement in pharmaceutical treatments, is priced competitively, with monthly costs ranging from $149 to $299 depending on the dosage. This pricing strategy aims to alleviate the financial burden often associated with weight loss medications, particularly when compared to the existing weekly injection alternatives that can be prohibitively expensive.
This oral medication's introduction comes just two weeks after it received approval from U.S. regulatory authorities, indicating a swift progression from development to market availability. Patients can find the initial 1.5-milligram dosage at over 70,000 pharmacies across the country, including popular chains such as CVS and Costco, alongside certain telehealth providers like LifeMD and Weight Watchers. Higher dosages of the Wegovy pill are expected to become available shortly thereafter.
For those opting to pay out-of-pocket, the initial dosage is set at an accessible $149 per month, with the 4-milligram dosage available for the same price until mid-April, after which it will increase to $199 per month. The higher dosages, specifically the 9 and 25 milligrams, will cost $299 monthly. Importantly, insured patients may pay as little as $25 for their prescriptions, highlighting the varied accessibility of this treatment option.
Interestingly, cash-paying individuals will also have the option to purchase the starting dosage through President Donald Trump's direct-to-consumer site, TrumpRx, under a deal made with Novo Nordisk last November. Although the site is set to launch in January, the exact start date remains uncertain.
Novo Nordisk emphasized that this new pill opens up exciting possibilities for the more than 100 million Americans living with obesity. In contrast, their injectable products, along with those offered by Eli Lilly—Novo Nordisk’s primary competitor—typically list for around $1,000 monthly, though reduced cash prices range from $299 to $499 depending on dosage.
The competition between these two pharmaceutical giants is heating up, as they both seek to capture larger shares of the expanding GLP-1 market, which analysts project could reach a staggering $100 billion by the 2030s. Oral medications, according to Goldman Sachs experts, might command approximately 24% of this market, equating to around $22 billion.
The rollout of Novo Nordisk's daily oral drug gives the company a significant advantage as it moves ahead of Eli Lilly, whose competing pill awaits FDA approval later this year. Furthermore, the FDA has also sanctioned the Wegovy pill for reducing the risk of critical cardiovascular events in adults with obesity and pre-existing cardiovascular conditions, mirroring the approval label for its well-known injectable counterpart, Wegovy. Both formulations utilize the active ingredient semaglutide, which functions by imitating the gut hormone GLP-1 to help control appetite.
Ed Cinca, the senior vice president of marketing & patient solutions at Novo Nordisk, stated, "This moment is about changing what's possible in weight management. We've worked hard to ensure that the Wegovy pill is both affordable and accessible, allowing individuals to choose how they wish to manage their care." However, users must adhere to a guideline of waiting 30 minutes before consuming food or beverages after taking the medication.
In clinical trials involving over 300 adults with obesity, the highest dosage of the oral semaglutide demonstrated an impressive average weight loss of 16.6% over 64 weeks. Even when considering all participants, regardless of whether they continued with the treatment, the average weight loss was still notable at 13.6%. Early indications suggest that this pill may outperform Eli Lilly's similar oral treatment, albeit with fewer dietary restrictions.
